Zenosense Inc. ZENO Archives

TuesdayOct 02, 2018 11:26 am

Zenosense, Inc. (ZENO) Attracts Investment Funds for Next Step in Development of MIDS Cardiac Point of Care Diagnostic Device

Agreement signed with third party investor to fund up to $1.2 million to support next crucial development phase of MIDS Cardiac POC diagnostic device Patented MIDS technology has successfully detected commercial assay beads at a level approximately four times better than the threshold advised as required for a high sensitivity troponin assay Cardiac biomarkers global market expected to reach $13.3 billion by 2024 HS Troponin testing for myocardial infarction at the point of care would meet a critical unmet medical need CDC reports that heart disease is the leading cause of death for both men and women A new economic…

TuesdayOct 02, 2018 9:57 am

QualityStocksNewsBreaks – Zenosense, Inc. (ZENO) MML JV Expands Technical Team

Healthcare technology company Zenosense (OTC: ZENO) this morning announced that, in support of the next phase of development of MIDS Cardiac, its MIDS Medical Ltd. (“MML”) joint venture (“JV") has expanded its technical team. MML has engaged three key contractors following its recent funding agreement. Two such contractors are independent electronics engineers with experience including embedded digital and analogue hardware and software design, multilayer PC design, immunoassay and magnetic particle experience, control systems and data acquisition. Additionally, MML has engaged The Magnetism Group at the University of Liverpool led by Dr. Liam O'Brien, which will assist MML in the calibration…

FridaySep 28, 2018 2:39 pm

QualityStocksNewsBreaks – Zenosense, Inc. (ZENO) MIDS Cardiac Device Could Spare Patients from Unnecessary Evaluation Expenses

Healthcare technology company Zenosense (OTC: ZENO), a co-owner of the United Kingdom’s MIDS Medical Limited (“MML”) and its innovative handheld MIDS technology, is engaged in the ongoing development of its innovative MIDS Cardiac device. A recent article about the company reads: “MIDS Cardiac aims is to deliver true laboratory accuracy, performing high-sensitivity troponin tests in the emergency room or out in the field to better identify if a patient with chest pain or shortness of breath is experiencing a myocardial infarction. Troponin is a heart protein generally searched for by emergency room physicians as a quick indicator if damaged cardiac…

MondaySep 24, 2018 11:46 am

Zenosense, Inc.’s (ZENO) Heart Attack Testing Technology Development Continues to Advance Hopes of Portable Point of Care Device

Company’s MIDS Cardiac device aims to help ER personnel perform quick, high-sensitivity analysis of heart events MIDS device’s handheld portability is being developed to allow quick-response resource to minimally trained ambulance personnel Final device could ultimately help save patients, health insurers from unnecessary evaluation expenses Heart disease remains the leading cause of death in men and women within the United States (http://ibn.fm/iTWKf), accounting for one out of every four deaths, and, as such, is fertile ground for research that is published regularly in professional periodicals such as the Journal of the American Heart Association (http://ibn.fm/xrAJK). The ailment is also the inspiration for…

WednesdaySep 05, 2018 9:57 am

QualityStocksNewsBreaks – Zenosense, Inc. (ZENO) MIDS Medical Ltd. JV Secures Up to $1.2M in Staged Funding

Zenosense (OTC: ZENO), a healthcare technology company, this morning announced that its MIDS Medical Ltd. (“MML") joint venture (“JV”) has entered a staged funding for the next phase of development of the MIDS Cardiac™ hand-held technology. MML entered into an agreement with a third-party investor for funding of up to a total of $1,200,000 on August 31, 2018. The funding is anticipated to cover the expenses of the next key development phase intended to prove that the MIDS magnetic detection method can detect and accurately quantify a live high sensitivity (“HS”) assay on the MIDS microfluidic test strip. Per the…

FridayAug 24, 2018 2:44 pm

QualityStocksNewsBreaks – Zenosense, Inc.’s (ZENO) MIDS Cardiac™ Uniquely Designed to Provide Lab-Comparable Accuracy in Minutes at Point of Care

Zenosense’s (OTC: ZENO) MIDS Cardiac™ may prove revolutionary in the niche cardiac diagnostic testing market, currently valued between $2 and $6 billion in the U.S. A recent article discussing this, reads “MIDS Cardiac™ is unique, because the technology is being developed to detect very low levels of cardiac markers to deliver accuracy that’s equal or superior to expensive state-of-the-art central laboratory analyzers, all while being accessible at the point of care and offering results within minutes.” To view the full article, visit http://ibn.fm/AYvAL About Zenosense, Inc. Zenosense Inc., through a joint-venture ownership in MIDS Medical Ltd., is primarily focused on…

WednesdayAug 15, 2018 12:17 pm

MIDS Cardiac by Zenosense, Inc. (ZENO): A Heart Attack Diagnostic Revolution?

The handheld testing device technology under development by Zenosense aims to deliver rapid results and state-of-the-art, laboratory-accurate results for the quick diagnosis of heart attacks Medical professionals believe that diagnosis within 30 minutes of a heart attack is the golden standard for ensuring adequate treatment Cardiac diagnostic testing market estimated between $2 billion and $6 billion in the U.S. alone MIDS Cardiac™, a handheld diagnostic device for cardiac emergency triage being developed by Zenosense, Inc. (OTCQB: ZENO), could prove to be revolutionary in the diagnostic process. Incorporating the patented MIDS technology, which is predicated on the nano-magnetic detection of assay…

FridayAug 10, 2018 11:19 am

QualityStocksNewsBreaks – Zenosense, Inc. (ZENO) Transforming Modern Cardiac Diagnostics

Zenosense (OTC: ZENO), through the development of MIDS Cardiac™, seeks to provide a technology that delivers laboratory-level accuracy at the point of care. An article discussing the company’s recent success reads: “A successful development of MIDS Cardiac is just the first step in the development of a wider technology platform that could be adapted to a wide range of point of care immunoassay tests, based on the same concepts of speed, accuracy, ease of use and cost-effectiveness. Zenosense and MIDS Medical Limited are planning to use the platform to develop a multi-capability, highly sensitive point of care device that could…

MondayAug 06, 2018 1:51 pm

Zenosense, Inc. (ZENO) Aims to Revolutionize Cardiac Diagnostics Market

Handheld technology platform in development to deliver high sensitivity, laboratory accuracy testing for cardiac biomarkers at the point of care Cardiac biomarker testing market expected to reach $7.2 billion this year Major potential for the patented technology to be applied to the detection of numerous other conditions, including cancer, HIV, hepatitis, autoimmune diseases and many others With cardiovascular disease being the leading cause of death globally for both men and women, and one in four Americans dying of heart disease every year (http://ibn.fm/GD0Ea), the need for more accurate and faster cardiac diagnostic methods is more than evident. Health care technology company…

ThursdayAug 02, 2018 12:51 pm

QualityStocksNewsBreaks – Zenosense, Inc. (ZENO) Continues to Reach Key Milestones

Zenosense (OTC: ZENO) is an innovative healthcare technology developer engaged in transformational, disruptive medical diagnostic projects. Recently, the company has achieved two major milestones. An article discussing the company’s recent success reads: “Health care technology company Zenosense, Inc. (OTCQB: ZENO) has completed two important milestones recently. The first was a successful second round of quantitative testing for the MIDS detection technology; the technology is core to the development of MIDS Cardiac™, a handheld device to rapidly test for certain cardiac biomarkers at the point of care. The second milestone relates to the company’s uplisting to the OTC Markets Group OTCQB…

Site Search

Company Search

Tag: Zenosense Inc. ZENO